AST Macerata
- Address
- Via Annibali,31/L, Province of Macerata, Italy
AST Macerata - Breast Cancer Research Center
AST Macerata is a clinical research center dedicated to advancing treatment strategies for aggressive forms of breast cancer. The center specializes in evaluating novel immunotherapy approaches for high-risk patient populations, with particular emphasis on improving long-term survival outcomes through adjuvant treatment protocols.
- Triple negative breast cancer immunotherapy trials
- Anti-PD-L1 antibody therapy research
- Adjuvant treatment strategies for high-risk breast cancer
The center's research focuses on triple negative breast cancer, one of the most challenging breast cancer subtypes to treat. Through participation in the A-Brave trial, AST Macerata is investigating whether one year of adjuvant Avelumab, an anti-PD-L1 antibody, can improve disease-free survival in patients who have completed curative treatment including surgery and chemotherapy. This work represents a critical effort to expand therapeutic options for patients with high-risk disease following both neoadjuvant and adjuvant chemotherapy approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in AST Macerata
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized Trial of Adjuvant Avelumab in High-Risk Triple Negative Breast Cancer Post-Curative Treatment | Universita Degli Studi Di Padova | Phase III | Not Recruiting | Jun 2016 | Oct 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Avelumab | 1 | Unknown | 2016-06-16 | 2016-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.